Tampa General Hospital’s 340B dispute with Eli Lilly dismissed by federal judge

Health and Human Services. As such, Tampa General’s case cannot move forward.

Tampa General Hospital’s lawsuit against biopharma manufacturer Eli Lilly over a dispute centered around the 340B Drug Pricing Program has been dismissed, with a federal judge ruling that Supreme Court precedent has confirmed that regulation of the pharmaceutical discount program falls under the purview of the U.S. Department of Health and Human Services (HHS).

The hospital initially sued under Florida consumer protection laws, which the judge ruled do not apply to this case. The lawsuit dates back to July, with Tampa General suing over a requirement the drug developer put in place, compelling all hospitals to submit detailed prescription information related to the drugs being discounted under the 340B framework.

Hospitals that participate in 340B are able to get discounted prescriptions for patients covered by Medicaid, with eligibility determined by the percentage of high-risk and low-income members of the community the facility treats, such as children, cancer patients, and whether or not its work qualifies as a critical safety net for the community.

The savings are intended to offset the costs to the benefit of patients with limited resources.

However, as part of its internal monitoring to ensure hospitals are meeting the requirements of the law, Eli Lilly was requiring regular reports in the form of prescription data related to 340B discounts.

Tampa General took issue with this policy, citing patient privacy. Further, it contended that the drug company was acting as a de facto regulator by forcing the submission of prescription data.

As such, it refused to comply, and Eli Lilly stopped offering its drugs at 340B discount rates.

The hospital said the shift could potentially increase its costs by tens of millions of dollars each year.

Subscribe to Health Exec News

SCOTUS ruling in focus

A similar lawsuit that made it all the way to the U.S. Supreme Court in 2011 was the basis for the district court dismissing Tampa General’s complaint. In that case, the Supreme Court ruled that disputes related to 340B discounts are for HHS to manage, as outlined in the law passed by Congress.

As such, drug developers cannot be sued when they withhold discounts, potentially even in an instance like this where the discounts are withheld as a result of a prescription drug data reporting requirement.

The U.S. District Court said that siding with Tampa General in allowing the case to move forward would not only undermine the Supreme Court ruling, but also the authority of HHS to regulate the program.

However, the judge dismissed the case without prejudice, opening the door for Tampa General to file a new complaint related to the matter if another legal avenue to remedy the situation is determined to be viable.

Tampa General has said in public statements that it intends to re-file its lawsuit, as it is not complying with Eli Lilly’s prescription data submission requirement.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Subscribe to Health Exec News

Subscribe to Health Exec News